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Improved Hemodynamic Outcomes with Glycopyrro-
late Over Atropine in Carotid Angioplasty and Stent-
ing
Christine Chung, Sharif H. Ellozy, Tejas R. Shah, Rajesh
Malik, Randall B. Griepp, Gabrielle DiLuozzo, Michael L.
Marin, Peter Faries.. 1Mount Sinai Medical Center, New
York, NY; 2New York University Medical Center, New
York, NY
Objectives: Prophylactic administration of atropine
and glycopyrrolate have been used to prevent bradycardia
and hypotension associated with carotid angioplasty and
stenting (CAS). This study compared the efficacy of glyco-
pyrrolate to atropine in preventing CAS-induced hemody-
namic instability and cardiac complications.
Methods: 86 patients undergoing CAS between 2005-
2009 were evaluated. 51 of these patients received prophy-
lactic atropine or glycopyrrolate administration prior to
CAS. Primary endpoints were stroke, MI, postoperative
bradycardia (HR 60 beats/min), and hypotension (sys-
tolic BP 90). Other outcomes were tachycardia
(HR100), hypertension (systolic BP160), absolute
pressure changes (pre- and postoperative systolic BP differ-
ence), arrhythmias, EKG/cardiac enzyme abnormalities,
neurologic changes, and access site complications.
Results: Mean age was 72 9 years (p ns). Baseline
systolic BP andHRwere equivalent in both groups (p ns;
figure 1). Bradycardia and hypotension were significantly
higher in atropine patients compared to glycopyrrolate
patients. There was a trend towards reduced hypertension
and pressure changes in the glycopyrrolate cohort com-
pared to atropine. Additionally, cardiac events were found
to be equivalent.
Conclusions: Prophylactic glycopyrrolate, compared
with atropine, reduces hemodynamic instability during CAS,
which may diminish cardiac effects. We recommend glycopy-
rrolate to prevent CAS-induced bradycardia and hypotension.
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Objectives: The purpose of this study was to charac-
terize geometry and plaque composition of the superficial
femoral artery (SFA) using intravascular ultrasound
(IVUS).
Methods: Sequential, cardiac-gated IVUS imaging of a
10cm SFA segment was collected systole using a motorized
pullback device (0.5mm/s), Eagle Eye catheter, and IVUS
console (Volcano Corp) from patients (n  59) undergoing
angiography for evaluation/treatment of peripheral arterial
disease (PAD). All imaging was performed prior to any inter-
vention. IVUS data was analyzed using the corresponding
post-processing software. Lumen and media-adventitia con-
tours were manually identified which allowed vessel geometry
and VH-IVUS plaque composition data to be extracted.
Overall mean geometric and plaque composition values were
calculated by averaging all cross sectional images over the
length of each pullback. Minimum and maximum diameters
represent extremes encountered from11, 763 analyzed IVUS
images.
Results: See able 1. Over 70% of all SFA vessel
diameters fall between 5mm and 7mm. The mean lumi-
nal and vessel cross sectional areas were 15.0 mm2 and
30.9 mm2 respectively yielding an overall mean area
stenosis of 51.4% for the cohort. Plaque burden in SFA
was 106.6 mm3/cm.
Conclusions: IVUS imaging provided a wealth of geo-
metric and morphologic data. This quantitative data may
better define characteristics of the SFA in patients with
PAD.
Table 1. Summary of SFA geometry and plaque
composition
Min Mean  STDEV Max
Diameter Lumen (mm) 1.5 4.2  0.9 7.5
Vessel (mm) 2.2 6.2  0.9 9.6
Plaque Area Stenosis (%) 13.7 51.4  10.7 90.7
Fibrous (%) 56.3  14.7
Fibro-Fatty (%) 10.8  7.8
Necrotic Core (%) 18.3  9.7
Dense Calcium (%) 14.6  11.5
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National Outcomes and Charges for Claudication and
Limbthreat: Angioplasty Versus Bypass Graft
Teviah Sachs, Frank Pomposelli, Mark Wyers, Allen Ham-
dan, Marc L. Schermerhorn. Beth Israel Deaconess Medi-
cal Center, Boston, MA
Objectives: Assess Outcomes & Costs in Patients with
Lower Extremity Vascular Disease Undergoing Intervention.
Methods: We used the NIS database (1998-07), se-
lecting those with atherosclerosis & intervention for clau-
dication (CL) [ICD-9: 440.21] or limbthreat (LT)
[440.22-24] with angioplasty / stent (PTA) [39.50,
39.90], aorto-femoral bypass (AFB) [39.25], & peripheral
bypass (BPG) [39.29]. We evaluated demographics, co-
morbidities, charges & adjusted mortality & major ampu-
tation.
Results: There were 563, 142 patients: PTA: 218, 656
(38%), BPG: 280, 022 (50%), AFB: 36, 307 (6%). PTA
patients were older than BPG (71 v 70y), more often
female (46 v 42%), had similar but lower mortality than
BPG for CL (.2 v .4%) and LT (2.1 v 2.5%). PTA had higher
major amputation for LT (7% v 4%) [all p 0.01]. Median
LOSwas lowest for PTA (CL:1d, LT:3d), followed by BPG
(CL:3d, LT:6d) and AFB (CL:5d, LT:7d) [all p  0.01].
Total procedures for CL rose 58% (24, 488 - 38, 785),
while charges rose 228% ($0.46 - $1.5 billion). Procedures
for LT rose 5% (34, 402 - 36, 147) while charges rose 112%
($1.1 to $2.3 billion) [Figure]. For CL and LT, PTA has
surpassed BPG & AFB combined.
Conclusions: PTA has altered the treatment paradigm
for lower limb ischemia with increased procedures &
charges. It is unclear if this represents an increase in patients
or number of treatments per patient. Although mortality is
lower with PTA, limb loss appears higher, necessitating
longitudinal studies to determine the appropriateness of
PTA for these patients. Themortality benefit with PTAmay
be ultimately lost if multiple interventions are performed
on the same patients.
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Objectives: The goal of our study was to assess the
current management strategies in dialysis-dependent pa-
tients with critical limb ischemia (CLI), and to identify
parameters associated with limb loss in this patient popula-
tion.
Methods: Dialysis-dependent patients who presented
with CLI (Rutherford 4-6) between 06/2001-06/2009
were retrospectively analyzed.
Results: There were 94 patients (82% males, 119
limbs, mean age 67  10). Co-morbidities included CAD
(87%), hypertension (86%), DM (78%), non-ambulatory
status (26%). Indications were rest pain (18%), non-healing
ulcer (23%), gangrene (53%), and advanced foot sepsis
(7%). Primary amputation (PA) was performed in 20%; 26%
underwent open bypass, 54% had endovascular (EV) inter-
ventions. More EV-treated patients had gangrene than
open group (63% vs 39%, p  0.047). The most distal
intervention was infrapopliteal in 47% of patients (open,
51%; endovascular, 62%, p 0.259). Two-year survival was
worse in PA group (21 8%, vs 51 9% in open, 41 7%
in EV, p  0.088). Limb salvage (LS) was similar in open
and EV groups (2-year LS 60  9.7% vs 58  8%, p 
0.690). Amputation-free survival (AFS) was also similar
(2-year AFS 38 9% in open vs 28 6% in EV, p 0.304).
Multivariate analysis showed only non-ambulatory status
(OR: 3.0, 95% CI, 1.4-6.8, p  0.007) and gangrene
(OR:2.7, 1.1-6.5, p  0.027) being independently associ-
ated with limb loss after limb salvage attempt. The LS rate
was 0% at 6 months in non-ambulatory patients with gan-
grene (n  15), whereas it was 70  8% in ambulatory
patients with gangrene (n  37). Only 6 of the 15 non-
ambulatory patients with gangrene who had LS attempt did
not have an amputation; all died within 3 months with
non-healed wounds.
Conclusions:EV interventions play a significant role in
the current management of dialysis-dependent patients
with CLI, with similar results to open reconstructions.
Non-ambulatory dialysis patients with gangrene carry a
dismal prognosis and primary amputation should be con-
sidered as the initial modality.
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